Share on StockTwits
 

AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded by equities researchers at Ladenburg Thalmann from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, American Banking & Market News reports. The analysts noted that the move was a valuation call.

AMAG has been the subject of a number of other recent research reports. Analysts at Zacks downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, December 24th. They now have a $29.40 price target on the stock. Analysts at Summer Street reiterated a “buy” rating on shares of AMAG Pharmaceuticals in a research note to investors on Thursday, October 24th. They now have a $43.00 price target on the stock, up previously from $31.00. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.07.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded down 8.28% during mid-day trading on Wednesday, hitting $20.05. The stock had a trading volume of 340,872 shares. AMAG Pharmaceuticals has a 52-week low of $15.26 and a 52-week high of $28.42. The stock has a 50-day moving average of $23.53 and a 200-day moving average of $23.54. The company’s market cap is $435.8 million.

In other AMAG Pharmaceuticals news, Insider Christopher White sold 4,000 shares of the stock in a transaction dated Thursday, January 9th. The shares were sold at an average price of $22.37, for a total transaction of $89,480.00. Following the completion of the sale, the insider now directly owns 24,834 shares in the company, valued at approximately $555,537. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.